context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. up to 70% of breast cancers express progesterone receptor (pr). if your cancer is pr+, apristor could be an option for you.
Company profile
Ticker
CNTX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Context Therapeutics LLC
SEC CIK
Corporate docs
IRS number
472566423
CNTX stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Context Therapeutics Announces $100 Million Private Placement
2 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Important Regulatory Milestone Supports Next Phase of CTIM-76 Development
1 Apr 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 Mar 24
8-K
March 2024 Corporate Presentation Advancing Medicines for Solid Tumors
6 Mar 24
Latest ownership filings
4
Jennifer Lynn Minai-Azary
22 Mar 24
4
Alex C. Levit
22 Mar 24
4
Martin A. Lehr
22 Mar 24
SC 13G/A
Affinity Asset Advisors, LLC
13 Feb 24
SC 13G/A
Lehr Martin A.
7 Feb 24
SC 13G
Opaleye Management Inc.
5 Jan 24
4
Philip W. Kantoff
31 May 23
4
Linda West
31 May 23
4
Jennifer Evans Stacey
31 May 23
4
RICHARD J BERMAN
31 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.68 mm | 21.68 mm | 21.68 mm | 21.68 mm | 21.68 mm | 21.68 mm |
Cash burn (monthly) | 1.15 mm | 1.48 mm | 2.06 mm | 1.84 mm | 1.15 mm | 1.48 mm |
Cash used (since last report) | 8.48 mm | 10.88 mm | 15.15 mm | 13.50 mm | 8.48 mm | 10.88 mm |
Cash remaining | 13.19 mm | 10.80 mm | 6.53 mm | 8.18 mm | 13.19 mm | 10.80 mm |
Runway (months of cash) | 11.4 | 7.3 | 3.2 | 4.5 | 11.4 | 7.3 |
Institutional ownership, Q4 2023
0.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 20 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 51.98 mm |
Total shares | 46.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Clear Harbor Asset Management | 36.00 k | $40.68 mm |
Aspire Wealth Management | 10.00 k | $11.30 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Martin A. Lehr | Stock Option Common Stock | Grant | Acquire A | No | No | 1.07 | 291,402 | 311.80 k | 291,402 |
21 Mar 24 | Alex C. Levit | Stock Option Common Stock | Grant | Acquire A | No | No | 1.07 | 153,515 | 164.26 k | 153,515 |
21 Mar 24 | Jennifer Lynn Minai-Azary | Stock Option Common Stock | Grant | Acquire A | No | No | 1.07 | 160,115 | 171.32 k | 160,115 |
31 May 23 | Jennifer Evans Stacey | Stock Option Common Stock | Grant | Acquire A | No | No | 0.87 | 25,000 | 21.75 k | 25,000 |
31 May 23 | Berman Richard J | Stock Option Common Stock | Grant | Acquire A | No | No | 0.87 | 50,000 | 43.50 k | 50,000 |